Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,188.00
Bid: 12,190.00
Ask: 12,192.00
Change: -2.00 (-0.02%)
Spread: 2.00 (0.016%)
Open: 12,304.00
High: 12,356.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms

Wed, 05th Apr 2023 17:01

(Alliance News) - Stocks in London closed largely lower on Wednesday, while the FTSE 100 ended in the green thanks to a solid performance from utility and pharmaceutical stocks.

"Appetite for risk is slowly decreasing, taking a break from the sharp bull run that started last week, while investors wait for further macro developments," said Pierre Veyret at ActivTrades.

The FTSE 100 index closed up 28.42 points, or 0.4% at 7,662.94 on Wednesday. Meanwhile, the FTSE 250 ended down 213.62 points, or 1.1%, at 18,601.42, and the AIM All-Share closed down 6.53 points, or 0.8%, at 803.69.

The Cboe UK 100 ended up 0.2% at 765.65, the Cboe UK 250 closed down 1.8% at 16,137.00, and the Cboe Small Companies ended marginally lower at 13,349.60.

The pound was quoted at USD1.2471 at the London equities close Wednesday, down from USD1.2501 at the close on Tuesday.

In the FTSE 100, RS Group dropped 6.2%, making it the worst blue-chip performer at the close on Wednesday.

For the year ended March 31, the industrial and electronics products distributor said it saw 10% like-for-like revenue growth. For the fourth quarter alone, group like-for-like revenue improved 1% on-year, but slowed from 8% growth in the third quarter.

Consequently, Chief Financial Officer David Egan said that the firm anticipates full year adjusted operating profit to be "slightly ahead of consensus expectations."

RS said adjusted operating profit consensus stands at GBP382.0 million, which, if achieved, would represent growth of 19% from GBP320.4 million the prior year.

AstraZeneca climbed 2.8% after it announced it received positive results from interim analysis of the DUO-O phase 3 trial of its Imfinzi drug.

The pharmaceutical company said the analysis showed that a combination of Imfinzi, alongside Lynparza, chemotherapy and bevacizumab met its primary endpoint.

It showed a "statistically significant and clinically meaningful" improvement in progression-free survival when compared with treatment with just chemotherapy and bevacizumab.

Pharmaceutical peers Haleon and GSK both rose 2.5% in a positive read-across.

Also near the top of London's flagship index were United Utilities, National Grid, Centrica and Severn Trent which closed 3.2%, 2.2%, 1.7%, 2.3% and higher, respectively.

In the FTSE 250, Hilton Food lost 5.5% after it reported its annual profit fell, as it announced the appointment of its new chief executive officer.

Hilton Food appointed Steve Murrells as CEO, with effect on July 3.

Murrells will be replacing Phillip Heffer, who is stepping down after five years in this role. Hilton Food said Heffer will remain with the company as co-founder and advisor to its Foods board.

The food packaging business said its revenue for the year ended January 1 grew by 17% to GBP3.85 billion from GBP3.30 billion the year prior.

This was primarily driven by higher raw material prices and volume growth following Hilton Food's recent acquisition of Foppen, the company said.

Meanwhile, its pretax profit fell by 38% to GBP29.6 million from GBP47.4 million.

This was attributed to challenges in the company's UK Seafood business, as a recovery from inflation took longer than expected, Hilton Food explained.

At the other end of the FTSE 250, Direct Line rose 6.2% after Citigroup raised the insurer to 'buy' from 'sell' with a price target of 188 pence. The stock closed at 152.40p.

Elsewhere in London, Topps Tiles rose 6.9% after it delivered a "record" period in the first half of its financial year, ended April 1.

Revenue climbed 9.5% year-on-year to GBP130.5 million from GBP119.2 million. Topps Tiles said the strong revenue performance reflected the "strength of brands, the execution of our strategy and encouraging domestic market conditions".

The tile seller also noted that about GBP9.0 million of revenue growth is related to the acquisition of Pro Tiler Tools and the launch of Tile Warehouse in 2022.

Chief Executive Rob Parker said: "The economic outlook remains uncertain but early signs of easing supply chain pressures, allied to the group's strong balance sheet, world class customer service, specialist expertise and growth strategy give us confidence in our ability to drive value for all stakeholders over the medium term."

On AIM, Fulham Shore soared 32% after it agreed to be taken over by Tokyo-listed food company Toridoll.

Toridoll will pay 14.15 pence per share, a 35% premium to Fulham Shore's Tuesday closing price of 10.50p. The deal gives the owner of restaurant chains Franco Manca and The Real Greek an equity value of GBP93.4 million.

In European equities on Wednesday, the CAC 40 in Paris ended down 0.4%, while the DAX 40 in Frankfurt ended down 0.5%.

The eurozone private sector economy expanded at the strongest pace since May 2022, driven by the services arm.

The seasonally adjusted S&P Global eurozone composite purchasing managers' index rose to 53.7 points in March, from 52.0 points in February.

This marks the highest level since May 2022, and a third successive month above the critical 50.0 threshold that splits growth from contraction.

The euro stood at USD1.0919 at the European equities close on Wednesday, lower against USD1.0957 at the same time on Tuesday.

Stocks in New York were mostly lower at the London equities close, with the Dow Jones Industrial Average up 0.1%, the S&P 500 index down 0.5%, and the Nasdaq Composite down 1.3%.

US service sector firms recorded faster growth in business activity during March, according to the latest data from S&P Global.

The seasonally adjusted final S&P Global US services PMI posted 52.6 in March, up from 50.6 in February. An earlier flash estimate had expected a reading of 53.8.

S&P Global said the rise in output was the sharpest since June. Firms attributed this to stronger client demand, a renewed rise in orders and the acquisition of new customers.

However, despite the stronger demand conditions, business confidence was below the series average and dipped from February amid inflation concerns.

"Business activity across the service sector expanded at a faster pace in March, as a return to new order growth offered a tonic to the US economy, which saw the fastest rise in private sector output since last June," said Sian Jones, senior economist at S&P Global Market Intelligence.

Against the yen, the dollar was trading at JPY130.94, lower compared to JPY131.83 late Tuesday.

Brent oil was quoted at USD84.48 a barrel at the London equities close on Wednesday, down slightly from USD84.52 late Tuesday. Gold was quoted at USD2,021.30 an ounce, higher against USD2,016.62.

In Thursday's UK corporate calendar, there are trading statements from Ferrexpo and Robert Walters.

In the economic calendar, the Halifax UK house price index will be published at 0700 BST before a UK construction PMI print at 0930 BST.

The US weekly unemployment insurance claims will be released at 1330 BST.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.